Tweet
Corium International Inc (NASDAQ:CORI) â€“ Stock analysts at Cantor Fitzgerald dropped their FY2019 earnings estimates for Corium International in a note issued to investors on Monday, August 13th. Cantor Fitzgerald analyst W. Tanner now expects that the biopharmaceutical company will post earnings of ($1.10) per share for the year, down from their prior forecast of ($1.09). Cantor Fitzgerald has a "Buy" rating and a $14.00 price objective on the stock. Get Corium International alerts:
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Corium International had a negative return on equity of 298.48% and a negative net margin of 155.21%. The company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $6.72 million. Several other equities analysts have also recently issued reports on the company. BidaskClub upgraded Corium International from a "strong sell" rating to a "sell" rating in a research report on Wednesday, June 13th. ValuEngine cut Corium International from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 17th. Zacks Investment Research upgraded Corium International from a "sell" rating to a "hold" rating in a research report on Friday, May 11th. Finally, HC Wainwright set a $14.00 price target on Corium International and gave the company a "buy" rating in a research report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Corium International has an average rating of "Buy" and a consensus target price of $12.80.
Shares of CORI stock opened at $8.69 on Wednesday. Corium International has a 1 year low of $7.17 and a 1 year high of $13.93. The firm has a market cap of $313.50 million, a PE ratio of -5.30 and a beta of 1.45. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11.
Several hedge funds have recently modified their holdings of CORI. MetLife Investment Advisors LLC acquired a new position in shares of Corium International during the 4th quarter valued at $123,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Corium International in the 1st quarter worth $167,000. Engineers Gate Manager LP acquired a new position in shares of Corium International in the 2nd quarter worth $215,000. Two Sigma Advisers LP acquired a new position in shares of Corium International in the 4th quarter worth $317,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Corium International by 126.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company's stock worth $317,000 after acquiring an additional 18,416 shares during the last quarter. Institutional investors own 95.26% of the company's stock.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening